Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys - PubMed (original) (raw)
Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys
E Eidelberg et al. Neuroscience. 1986 Aug.
Abstract
Fourteen macaque monkeys were injected intravenously with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. All developed the cardinal signs of parkinsonism (akinesia, rigidity, etc.) in varying degrees; some required repeated series of injections of the drug, while others developed the syndrome readily after the first series. Most of the subjects that were kept for longer than 4 weeks after the first dose of the drug showed complete or partial recovery after that time. Measurement, in some of the subjects, of the neostriatal levels of dopamine and dihydroxyphenylacetic acid showed the expected depletion of these substances at the peak of the behavioral action of the drug, but no recovery when the animals had returned to, or near, pre-drug behavioral status. No firm conclusion can be reached at this time as to the reasons for the behavioral recovery or the variability of the effects of the drug across subjects.
Similar articles
- Systemic 1-methyl,4-phenyl,1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates.
Ghilardi MF, Chung E, Bodis-Wollner I, Dvorzniak M, Glover A, Onofrj M. Ghilardi MF, et al. Life Sci. 1988;43(3):255-62. doi: 10.1016/0024-3205(88)90315-3. Life Sci. 1988. PMID: 3260986 - [Operant behavioral disorders in monkeys with an MPTP-induced Parkinson-like syndrome].
Burov IuV, Shul'govskiĭ VV, Petrov GV, Tereshchenko LV, Iudin AV. Burov IuV, et al. Fiziol Zh Im I M Sechenova. 1995 Oct;81(10):113-6. Fiziol Zh Im I M Sechenova. 1995. PMID: 9026250 Russian. No abstract available. - Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism.
Schultz W, Studer A, Jonsson G, Sundström E, Mefford I. Schultz W, et al. Neurosci Lett. 1985 Aug 30;59(2):225-32. doi: 10.1016/0304-3940(85)90204-6. Neurosci Lett. 1985. PMID: 3877257 - [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
Nishi K, Kondo T, Narabayashi H. Nishi K, et al. No To Shinkei. 1987 Jul;39(7):663-72. No To Shinkei. 1987. PMID: 3314916 Review. Japanese. - [MPTP and Parkinson's disease].
Imai H. Imai H. No To Shinkei. 1988 Nov;40(11):1011-24. No To Shinkei. 1988. PMID: 3064783 Review. Japanese. No abstract available.
Cited by
- Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson's disease through AKT/mTOR pathway.
Shi L, Huang C, Luo Q, Xia Y, Liu W, Zeng W, Cheng A, Shi R, Zhengli C. Shi L, et al. Aging (Albany NY). 2020 May 18;12(10):9515-9533. doi: 10.18632/aging.103225. Epub 2020 May 18. Aging (Albany NY). 2020. PMID: 32424108 Free PMC article. - Behavior, PET and histology in novel regimen of MPTP marmoset model of Parkinson's disease for long-term stem cell therapy.
Yun JW, Ahn JB, Kwon E, Ahn JH, Park HW, Heo H, Park JS, Kim H, Paek SH, Kang BC. Yun JW, et al. Tissue Eng Regen Med. 2015 Dec 28;13(1):100-109. doi: 10.1007/s13770-015-0106-3. eCollection 2016 Feb. Tissue Eng Regen Med. 2015. PMID: 30603390 Free PMC article. - Brain structural changes in cynomolgus monkeys administered with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A longitudinal voxel-based morphometry and diffusion tensor imaging study.
Jeong HS, Lee SR, Kim JE, Lyoo IK, Yoon S, Namgung E, Chang KT, Kim BS, Yang S, Im JJ, Jeon S, Kang I, Ma J, Chung YA, Lim SM. Jeong HS, et al. PLoS One. 2018 Jan 10;13(1):e0189804. doi: 10.1371/journal.pone.0189804. eCollection 2018. PLoS One. 2018. PMID: 29320500 Free PMC article. - MPTP Induces Systemic Parkinsonism in Middle-Aged Cynomolgus Monkeys: Clinical Evolution and Outcomes.
Yue F, Zeng S, Tang R, Tao G, Chan P. Yue F, et al. Neurosci Bull. 2017 Feb;33(1):17-27. doi: 10.1007/s12264-016-0069-y. Epub 2016 Oct 3. Neurosci Bull. 2017. PMID: 27699717 Free PMC article. - Squamosamide derivative FLZ protected tyrosine hydroxylase function in a chronic MPTP/probenecid mouse model of Parkinson's disease.
Bao XQ, Wu LY, Wang XL, Sun H, Zhang D. Bao XQ, et al. Naunyn Schmiedebergs Arch Pharmacol. 2015 May;388(5):549-56. doi: 10.1007/s00210-015-1094-5. Epub 2015 Feb 13. Naunyn Schmiedebergs Arch Pharmacol. 2015. PMID: 25678053